Roche has historically earned windfall profits from Tamiflu during flu epidemics causing jumps in demand. During the H1N1 swine flu outbreak in 2009, the drug produced almost $3 billion in revenue for the Swiss drugmaker.
Alvogen, which developed the generic treatment with Indian drugmaker Natco Pharma, said it expected the lower-priced product to save the U.S. healthcare system up to $500 million throughout the upcoming flu season, according to the report.
Facing more and more generic competition, Roche is now looking toward a new pipeline of blockbuster medications to increase revenues, reports Reuters.
More articles on supply chain:
Bristol-Myers Squibb to pay $19.5M for promoting off-label use of Abilify
China fines Medtronic $17M for price fixing medical devices
More than 150k US workers quit factory jobs in October
